Drug intelligence / Profile preview

Jian-Huang-Fang

Development stage: Preclinical
Lead developer: Caleco Pharma
Modality: Small Molecules

Overview

Jian-Huang-Fang (JHF) is a plant-extract-derived compound developed by Caleco Pharma Corp. under an exclusive license agreement with Natac Biotech S.L. It is intended to exert anti-inflammatory and metabolic effects, targeting cardiovascular and metabolic health. The compound is being developed for both clinical testing and as a nutritional food supplement.

Beyond the preview

Go deeper on Jian-Huang-Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jian-Huang-Fang.

Explore the full profile